FibroBiologics Inc(FBLG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:15 PM ET (Korea 10/1 05:15)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.64 | Insider Own | 16.72% | Shs Outstand | 6.1M | Perf Week | -2.26% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -8.33% | Insider Trans | - | Shs Float | 5.5M | Perf Month | -24.42% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.63 | Inst Own | 12.96% | Short Float | 11.95% | Perf Quarter | 43.44% |
| Income | -0.02B | P/S | - | EPS this Y | 64.29% | Inst Trans | 0.53% | Short Ratio | 3.32 | Perf Half Y | -1.52% |
| Sales | 0.00B | P/B | 1.71 | EPS next 5Y | 21.91% | ROA | -166.14% | Short Interest | 0.66M | Perf YTD | -71.1% |
| Book/sh | 0.76 | P/C | 2.46 | EPS past 3/5Y | -38.37% -71.12% | ROE | -660.08% | 52W High | -89.52% ($12.40) | Perf Year | -88.1% |
| Cash/sh | 0.53 | P/FCF | - | Sales past 3/5Y | - | ROIC | -317.34% | 52W Low | 109.66% ($0.62) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 22.1% | Gross Margin | - | Volatility(W/M) | 9.61% 11.79% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | EPS Q/Q | 72.78% | Profit Margin | - | RSI (14) | 43.44 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.64 | Sales Q/Q | - | SMA20 | -14.52% ($1.52) | Beta | 1.73 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/7/31 | SMA50 | 3.57% ($1.26) | Rel Volume | 0.5 | Prev Close | $1.31 |
| Employees | 15 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | 29.03% - | SMA200 | -54.97% ($2.89) | Avg Volume(3M) | 0.20M | Price | $1.3 |
| IPO | 2024/1/31 | Option/Short | No/Yes | Trades | 420 | Volume | 99,469 | Change | -0.76% |
FibroBiologics () is a US clinical-stage biotech company developing cell therapies using human fibroblasts (skin and connective tissue cells). It has a number of pipeline programs targeting chronic conditions such as diabetic foot ulcers, multiple sclerosis, intervertebral disc degeneration, and psoriasis, and holds approximately 270 US and international patents. With virtually no revenue, it is a micro-cap clinical biotech and a highly volatile stock.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded less than usual That is 50% of its average volume.
FBLG has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +64.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #519 of 592 in the industry
Based on market cap of $9M.
ENLV#517 Enlivex Ltd $9M PER - 
JAGX#518 Jaguar Health Inc $9M PER - FBLG#519 FibroBiologics Inc $9M PER - 
CMMB#520 Chemomab Therapeutics Ltd ADR $9M PER - 
LGVN#521 Longeveron Inc $9M PER - 
FAQ
What kind of company is FBLG?
FBLG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FBLG?
The market cap of FBLG is approximately $9M, ranking 5,532 within its sector.
What is the 52-week high and low for FBLG?
FBLG has recorded a 52-week high of $12.40 and a low of $0.62.
